A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Cancer Immunology Research
Wing Keung ChanJianhua Yu

Abstract

Multiple myeloma (MM) is an incurable hematologic malignancy of plasma cells, with an estimated 30,000 new cases diagnosed each year in the United States, signifying the need for new therapeutic approaches. We hypothesized that targeting MM using a bispecific antibody (biAb) to simultaneously engage both innate and adaptive cytolytic immune cells could present potent antitumor activity. We engineered a biAb by fusing an anti-CS1 single-chain variable fragment (scFv) and an anti-NKG2D scFv (CS1-NKG2D biAb). Although NKG2D is a potent activation receptor ubiquitously expressed on mostly cytolytic immune cells including NK cells, CD8+ T cells, γδ T cells, and NKT cells, the CS1 tumor-associated antigen on MM represents a promising target. CS1-NKG2D biAb engaged human MM cell lines and NKG2D+ immune cells, forming immune synapses. In effector cells, CS1-NKG2D biAb triggered the phosphorylation of AKT, a downstream protein kinase of the activated NKG2D-DAP10 complex. The EC50 values of CS1-NKG2D biAb for CS1high and for CS1low MM cell lines with effector PBMCs were 10-12 and 10-9 mol/L, respectively. CS1-NKG2D biAb acted through multiple types of immune cells, and this induced cytotoxicity was both CS1- and NKG2D-specific. In vivo, ...Continue Reading

References

May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel A ValleraHua Chen
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Khuda D KhanMichael A Caligiuri
Jan 16, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Vera RebmannHans Grosse-Wilde
Mar 21, 2008·Trends in Molecular Medicine·Carlos López-LarreaSegundo Gonzalez
Jul 25, 2008·Blood·Michael A Caligiuri
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Aug 20, 2011·Leukemia·N W C J van de DonkH M Lokhorst
May 18, 2013·Scandinavian Journal of Immunology·G ChitadzeD Kabelitz
Jun 5, 2013·Critical Reviews in Oncology/hematology·André Veillette, Huaijian Guo
Aug 27, 2013·Blood·Martha Q Lacy, Arleigh R McCurdy
Jan 1, 2014·Acta Biochimica Et Biophysica Sinica·Xiubao ChangA Keith Stewart
Mar 29, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jianhong ChuJianhua Yu
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Aug 27, 2015·The New England Journal of Medicine·Noopur Raje, Dan L Longo
Oct 6, 2016·The New England Journal of Medicine·S Vincent Rajkumar, Robert A Kyle
Feb 18, 2017·Leukemia·C TouzeauC Dumontet
Apr 6, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Friberg, D Reese

❮ Previous
Next ❯

Citations

May 14, 2019·Expert Opinion on Biological Therapy·Laahn H Foster, Lawrence G Lum
Oct 2, 2019·Journal of Clinical Medicine·Ana P Gonzalez-RodriguezSegundo Gonzalez
Aug 31, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Xuhong ZhaoShengsong Tang
Jan 7, 2020·Médecine sciences : M/S·Patrick Chames, Thierry Wurch
Jul 30, 2020·Expert Opinion on Biological Therapy·Mariya LazarovaAlexander Steinle
Jul 26, 2019·Cancers·Ziqing ChenAndreas Lundqvist
Jul 14, 2020·Frontiers in Oncology·Nicholas J W EasomRamou Njie
May 12, 2020·Frontiers in Immunology·Chiara CaraccioChristian M Schürch
Apr 11, 2020·Cancers·Christian Sordo-BahamondeSegundo Gonzalez
Mar 7, 2020·Frontiers in Immunology·Cai ZhangChongdeng Shi
Jul 15, 2020·Journal of Clinical Medicine·Xiang ZhouSophia Danhof
Nov 26, 2020·Cellular & Molecular Immunology·Benjamin RufTim F Greten
Aug 1, 2020·Blood·Leo RascheHermann Einsele
Dec 4, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lukas PekarMatthias Peipp
Dec 17, 2019·Current Opinion in Biotechnology·Christoph Rader
Jan 19, 2021·Oncoimmunology·Adeline RaynaudBrigitte Kerfelec
Jan 29, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhenhui WuYingjian Zeng
Feb 11, 2021·Cancers·Raquel LopesCristina João
Mar 7, 2020·Best Practice & Research. Clinical Haematology·Kitsada WudhikarnAlexander M Lesokhin
Feb 17, 2020·Antibody Therapeutics·Siwei NieJijie Gu
May 29, 2021·Molecular Aspects of Medicine·Luana TomaipitincaGiovanni Bernardini
Jun 20, 2021·European Journal of Immunology·Olivier DemariaEric Vivier
Aug 6, 2021·Immunological Reviews·Caroline Markmann, Vijay G Bhoj
Sep 3, 2021·British Journal of Haematology·Dawn SwanSimon Harrison
Sep 28, 2021·Therapeutic Delivery·Neret Pujol-NavarroPaul A Mulheran
Jul 25, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lijie XingYu-Tzu Tai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.